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Abstract The Region 4 Midwest Genetics Collaborative,
made up of seven regional states (Illinois, Indiana, Kentucky,
Michigan,Minnesota, Ohio, andWisconsin), brought together
pediatric endocrinologists, state laboratory experts, public
health follow-up specialists, and parents of children with
congenital hypothyroidism (CH) to identify the three-year
follow-up management and education patterns of primary care
clinicians and pediatric endocrinologists in the care of children
diagnosed with CH by state newborn screening (NBS) pro-
grams. Among a number of challenges, each state had differ-
ent NBS methods, data systems, public health laws, and
institutional review board (IRB) requirements. Furthermore,
the diagnosis of CH was complicated by the timing of the
NBS sample, the gestational age, weight, and co-morbidities
at delivery. There were 409 children with CH identified
through NBS in 2007 in the seven state region. The clinician
of record and the parents of these children were invited to
participate in a voluntary survey. Approximately 64 % of
clinician surveys were collected with responses to questions
relating to treatment, monitoring practices, educational re-
sources, genetic counseling, and services provided to children
with confirmed CH and their families. Nearly one-quarter
(24 %) of parents surveyed responded to questions relating to
treatment, education, genetic counseling, resources, and
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services they received or would like to receive. De-identified
data from six of the seven states were compiled for analysis,
with one state being unable to obtain IRB approval
within the study timeline. The data from this collabora-
tive effort will improve state follow-up programs and
aid in developing three-year follow-up guidelines for
children diagnosed with CH. To aid in the facilitation
of similar public health studies, this manuscript high-
lights the challenges faced, and focuses on the pathway
to a successful multi-state public health endeavor.
Keywords Congenital hypothyroidism . Public health .
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Introduction
Newborn screening (NBS) for congenital disorders is an
essential public health system intended to reduce death
and disability in newborns with a wide range of genetic
conditions. The utility of screening for congenital hypo-
thyroidism (CH) was first demonstrated in the early 1970s
(Klein et al. 1974). As the benefits of early diagnosis and
treatment of CH were established, it was gradually
adopted into NBS throughout the United States and is
now mandated or recommended in all 50 states; the Dis-
trict of Columbia; and U.S. territories, which include
America Samoa, Guam, Northern Mariana Islands, Puerto
Rico, and the U.S. Virgin Islands. (NNSGRC 2011; US
Task Force 1996, 2008). Approximately, 1,900 infants
with CH in the United States are detected annually
(NNSGRC 2006). Recent research demonstrates that,
while previously thought of as a predominantly sporadic
disease leading to dysgenesis (85–90 % of cases), there
are distinct genetic forms of isolated or syndromic thyroid
dysgenesis. These findings, while supporting non-
Mendelian modes of inheritance, have helped to further
elucidate the genetic basis of this condition (Szinnai
2014). Regardless of etiology, though, infants must be
quickly and properly identified and treated in order to
prevent permanent cognitive and physical delays. In ad-
dition, clinical follow-up by an endocrinologist for the
first three years of life, if not lifelong, is essential to
ensure that these children receive appropriate monitoring
and management. The American Academy of Pediatrics
(AAP) and the European Society for Pediatric Endocri-
nology (ESPE) provide guidelines for the treatment of
CH. These guidelines include a recommendation for
follow-up of CH cases until at least three years of age to
distinguish permanent versus transient disease states
(Rose and Brown 2006; ESPE Guidelines 1999).
The immediate impact on the health of infants diagnosed
with CH by NBS is undisputed, yet little follow-up data are
available assessing the long-term effectiveness of the program
at the state, regional, or national level. It is important to note
that some parents of children with CH choose to discontinue
thyroid hormone replacement without appropriate medical
advice and are lost to follow-up (Kemper et al. 2010;
Korzeniewski et al. 2013). The Health Resources and Services
Administration (HRSA)-funded Region 4 Midwest Genetics
Collaborative brought together pediatric endocrinologists,
state laboratory personnel, public health follow-up specialists,
and parents of children with CH to better understand follow-
up for patients with CH. The Region 4 Midwest Genetics
Collaborative (Region 4), which includes Illinois, Indiana,
Kentucky, Michigan,Minnesota, Ohio, andWisconsin, strives
to improve the health of children and their families by pro-
moting the translation of genetic medicine into public health
and health care services. The Region 4 Midwest Genetics
Collaborative continues to utilize the infrastructure that
launched projects like the Laboratory Performance Database
Region 4 Stork (R4S) (Fleischman et al. 2014; Hall et al.
2014; McHugh et al. 2011) and the Inborn Errors of Metab-
olism Information System (IBEM-IS) (Berry et al. 2010). As
the vanguard for a regional initiative to develop formal long-
term follow-up guidelines, Region 4 established the Congen-
ital Hypothyroidism 3-year Follow-up Workgroup (R4 CH
Workgroup) in 2011.
The R4 CH Workgroup sought to identify the man-
agement, genetic counseling, and medical education pat-
terns of pediatric endocrinologists and primary care
providers for the care of children diagnosed with CH
by state NBS programs within the seven state region.
Specifically, the R4 CH Workgroup sought to identify
management practices for re-evaluating the diagnosis of
CH at or before three years of age. To accomplish this,
the Workgroup overcame a variety of logistical, regula-
tory, and legal challenges to successfully complete the
study. Among a number of these challenges, each state
had different NBS methods, data systems, public health
laws, and institutional review board (IRB) requirements.
Despite these barriers, the data obtained from this col-
laborative effort will be used to improve state follow-up
programs within the region and aid in developing three-
year follow-up guidelines for children diagnosed with
CH nationwide. To aid in the facilitation of similar
public health studies, this manuscript highlights the
challenges faced and focuses on the pathway to a suc-
cessful multi-state collaborative endeavor.
Materials and Methods
Regional Leadership and State Participants
The study was developed and executed under the guidance of
the Region 4 Midwest Genetics Collaborative and utilized the
Congenital Hypothyroidism Long-Term Follow-up Project 465
infrastructure provided by the HRSA grantee, the Michigan
Public Health Institute (MPHI) (Fig. 1). The Office of Re-
search Integrity at MPHI approved the study protocol. Repre-
sentatives from each state in the region were included in the
CH 3-year Follow-up Workgroup. While the CH Workgroup
met face-to-face during the Region 4 Genetics Collaborative
Regional Meeting, the majority of the study protocol and
materials were developed during monthly teleconferences,
webinars and through email communique. Multi-state partic-
ipation was crucial to the success of the project to ensure
sufficient sample size, a range of responses, and a nuanced
comparative analysis. A Project Lead from the CHWorkgroup
was chosen to direct the study, but State Leads were also
necessary in order to focus the effort within the particular state
and to maintain momentum for completion of the study. State
Leads were identified at the outset of the study based on their
role within the state NBS program or in managing children
with CH, and their willingness to commit time and effort to the
project.
Subjects
The inclusion criterion for parent and provider participation in
the study was a diagnosis of CH through state NBS and a birth
date between January 1, 2007 through December 31, 2007. Of
note, the NBS blood sample for each subject was required to
have been obtained within the first 48 hours of life, as states
have varying collection protocols for children requiring sup-
port, such as total parenteral nutrition and blood products,
which may affect CH screening results. State variations also
include differing protocols or provider decisions regarding
repeat NBS blood samples or serum draws for specific con-
genital disorders for confirmatory testing. As this was a survey
study, the diagnosis of CH was purely based on NBS records
and survey responses, and direct medical records were not
reviewed. Children born in 2007 were chosen to allow for at
least three years since diagnosis by NBS before study partic-
ipation. The NBS record contains demographic data such as
the child’s name, date of birth, mother’s name, maternal
address and phone number provided at birth, and the clinician
identified at birth as being responsible for the child’s care. A
separate record contains the child’s positive NBS test(s) result
tied to the dried blood spot sample. After obtaining IRB
approval, the state laboratory and/or health department
accessed its own records to identify children who met the
inclusion criteria.
Study Design
The study was a survey collection with two mirrored surveys,
one for clinicians and one for families (Fig. 2). Pediatric
endocrinologists, state laboratory personnel, and public health
follow-up specialists in the Region 4 CH 3- year Follow-up
Workgroup met regularly to discuss, develop, and revise
survey instruments. In addition, the Workgroup sought and
received input from parents of children diagnosed with CH for
study and survey design. The Clinician Survey used in this
study was adapted following a 2009 CH pilot study performed
by our Region 4 colleagues from Michigan (Korzeniewski
et al. 2013). The Clinician Survey includes questions relating
to treatment, monitoring practices, educational resources, ge-
netic counseling, and services provided to the child with CH
and his/her family.
The Parent Survey was developed by the CH Workgroup
with the goal of understanding parent preferences for educa-
tional resources and reasons children were lost to follow-up. It
included questions relating to treatment, educational re-
sources, genetic counseling, and services parents received,
or would like to receive, from their state’s health department
as well as questions pertaining to diagnosis and treatment of
CH.
Protocol and Study Instrument Development
To streamline protocol and study instrument development, the
Project Lead was responsible for developing the core protocol
draft design, followed by detailed review by the State Leads
and additional members of the CH Workgroup. Core data
elements within the surveys could not be altered so that data
integrity was maintained. Staff fromMPHI worked with State
Leads to obtain IRB approval within their respective states as
well as to ensure that the overall protocol met federal require-
ments for protection of human subjects. Individual states
worked within their own systems to meet their institutional
IRB requirements and/or state laws as applicable. Each state
laboratory and/or public health department identified children
with CH from the state NBS database, which included records
that were stored either electronically or in a hard copy. As a
multi-state public health project, we were cognizant that the
general design would have to be relatively basic and the
protocol language would have to allow for some flexibility
for each State Lead to receive IRB approval. The number of
states involved and the variability in NBS program practices
ultimately resulted in several protocol modifications before
receiving CH Workgroup approval.
Each state health department mailed a cover letter with
informed consent, Clinician Survey, and self-addressed
stamped return envelope to the clinician identified through
the procedure noted above. Two weeks after the initial survey
distribution, each state health department mailed a second
copy of the Clinician Survey and return envelope to non-
respondents. Two weeks after the second survey distribution,
each state health department called clinician non-respondents
to provide a verbal request to complete and return the survey.
If a different managing clinician was identified either in the
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returned survey or phone call, the state health department
mailed a new Clinician Survey to that identified clinician.
A similar, but abbreviated, method was used for the Parent
Survey distribution. Depending on their IRB approval, each
state health department mailed a cover letter with informed
consent, Parent Survey, and self-addressed stamped return
envelope to the parent identified through the procedure noted
above. Two weeks after the initial survey distribution, state
health departments mailed a second copy of the Parent Survey
and return envelope to non-respondents. Two states sent the
Fig. 1 Region 4 genetics
collaborative - CH 3-year follow-
up
Fig. 2 Flow chart of study design & collaborative effort
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parent survey via certified mail so that they were able to
ascertain whether or not the parent had received the survey
and were non-respondent or if the parent no longer lived at the
address of record. The first Clinician and Parent Surveys for
any state were mailed in 2012.
The Clinician and Parent Surveys had a cover page which
included the subject’s name and date of birth. This cover page
assisted the state’s health department in tracking survey re-
sponses. When the surveys were returned, the state health
department removed the cover page containing the respon-
dent’s identifying information. The state health department
assigned an identification (ID) code to unique to the survey.
The ID code was used in lieu of the subject’s name on all study
data to link clinician and parent responses, where applicable.
The de-identified data were sent to MPHI for analysis.
Data Analysis
De-identified data were sent from each state to the Region 4
headquarters at MPHI for aggregate analysis. De-identified
raw data were received on a rolling basis from six of seven
states. A recordwas entered for each unique ID code, allowing
for paired surveys from clinicians and parents to be matched
within the same record. Once data collection was complete, an
MPHI epidemiologist used statistical software to analyze the
data, and survey responses were reported out to CH
Workgroup members for review and discussion. Additional
data analysis was completed upon discussion with the
Workgroup based on initial review.
Results
General
Overall, the study took 26 months from the initial CH
Workgroup meeting to the completion of the aggregate data
analysis (Fig. 3). Although study development began in early
2011, the first surveys were not mailed until 2012. The CH
Workgroup met in person twice and by teleconference 21
times with additional email communications between
members throughout the duration of the study. Development
of the study protocol and data collection elements was per-
formed in seven months, with all members of the CH
Workgroup providing input. The general study protocol re-
quired 11 revisions, including nine Clinician Survey and
seven Parent Survey revisions. Revisions ranged from simple
grammatical adjustments for improved responder comprehen-
sion to the removal and addition of significant data elements
determined by the CH Workgroup. Including the MPHI IRB
approval for overall study responsibilities and, specifically, for
Michigan participation, five of the seven states sought and
received IRB approval from their respective Health Depart-
ments. For those states obtaining IRB approval, it was re-
ceived within a mean of 4.6 months (range, 1–13 months). An
additional state collected data elements of interest as part of
their long-term follow-up program, and, for this state, MPHI
was able to submit a request to obtain de-identified long-term
follow-up data elements from their long-term follow-up pro-
gram for children born in 2007. One state encountered barriers
obtaining IRB approval through their NBS program due to
state laws restricting data access to public health records and
allowances to contact health care providers and families. For
this reason, no data were ultimately collected from this state
for the study. In total, the CHworkgroupwas able to aggregate
data from six of the seven states in Region 4.
Survey and Data Collection
A total of 409 children were identified in Region 4 as having
been diagnosed with CH in 2007. This resulted in a combined
birth prevalence of 1:1,836 for the seven states in Region 4
(Table 1). For those states receiving IRB approval, Clinician
and Parent Surveys were mailed according to their approved
contact protocol. Aside from the self-addressed stamped en-
velopes, no other incentive for the return of the Clinician and
Parent Survey was used. One of the six participating states did
not have access to parent names and addresses, so only clini-
cian survey responses were collected. Overall, this allowed
clinician data collection on 37.9 % and parent data collection
on 18.8 % of the diagnosed infants in Region 4 for this year.
Of the 409 infants identified as having been diagnosed with
CH, Clinician Surveys were mailed for 334 unique patients
Fig. 3 CH 3-year follow-up study timeline
468 Wintergerst et al.
with a response rate of 63.7 %; parent surveys were mailed for
291 patients with 24.4 % returned (Table 2). Survey collection
took a mean of seven months after initial disbursement (range,
1–8 months). We received paired Clinician and Parent Sur-
veys fo r the same infan t on 14 % of su rveys
returned.tgrouptgroup
Discussion
With 751,144 live births in Region 4 during 2007, we antic-
ipated identifying approximately 380 children whose NBS
was positive for CH. This was based on 2006 NBS data
demonstrating a national birth prevalence of 1:2,209 and a
regional birth prevalence of 1:1,972 (NNSGRC 2006). How-
ever, 409 children in our region were confirmed to have CH in
2007, indicating a birth prevalence of 1:1,836 (range,
1:1,472–2,438). Demographic differences, testing methods
(TSH versus TSH/T4), and state-specific cutoff values are
likely to be among the major reasons for this variability. The
diagnostic sensitivity was also potentially influenced by the
timing of the first NBS blood sample, gestational age, weight
of the infant, use of certain therapies, such as blood products,
and infant co-morbidities. While infants with only transient
abnormalities with their thyroid function studies were likely
included, this very fact reinforces the importance of re-
evaluating the diagnosis at or before three years of age.
While the time to study completion was significant, we
successfully retrieved unique survey data on 37.9 % of infants
born with CH. To our knowledge, this is the first multi-state
study assessing NBS long-term follow-up factors related to
clinical management and education practices of CH.
The two greatest challenges in completing this study in-
cluded the development of complimentary mirrored Clinician
and Parent Surveys and ensuring that all state and federal
privacy laws and Health Insurance Portability and Account-
ability Act (HIPAA) requirements were followed. This would
not have been possible without state laboratory and health
department representative involvement in the CHWorkgroup.
These representatives were knowledgeable about state regula-
tions governing the access of public health data for this
purpose. In addition, they provided valuable input during
survey development. The creation of surveys that provided
us with informed data was complex and difficult. All members
of the CH Workgroup, including clinicians, public health
personnel, and parent volunteers, were required to provide
their input. The Clinician Surveys were then vetted by clini-
cian volunteers, working with CHWorkgroupmembers, using
fictitious patients with varying backgrounds and treatment
plans. The Parent Surveys were vetted using a convenience
sample of parent volunteers to evaluate adaptability, ease of
use, and to address any evident potential literacy or cultural
issues. The majority of the time for protocol design was
dedicated to refining the surveys. As the validity of this form
of study is dependent on the data collected from the surveys,
we would strongly recommend a similar design model for
comparable studies in other regions (Table 3).tgroup
Regulatory and Legal Issues
As stated above, the inclusion of state laboratory and public
health personnel in the CH Workgroup was an absolute ne-
cessity for this study to be successful. While there are partic-
ular federal privacy laws, including HIPAA, that had to be
followed, each state also has specific laws governing protec-
tion of private health information. In recent years, NBS has
come under greater scrutiny by the public, largely due to
concerns regarding storage, consent, and use of genetic
Table 1 Region 4 NBS CH birth prevalence for 2007
State NBS 1st tier screening method Live births CH diagnosis Incidence
Illinois TSH 180,530 94 1:1,920
Indiana TSH 89,719 42 1:2,136
Kentucky T4/TSH 58,507 24 1:2,438
Michigan TSH 125,172 85 1:1,473
Minnesota TSH 73,675 46 1:1,602
Ohio TSH 150,784 75 1:2,010
Wisconsin TSH 72,757 43 1:1,692
Total ———— 751,144 409 1:1,836
NBS Newborn Screening, CH Congenital Hypothyroidism
Table 2 Survey collection statistics
Surveys mailed Surveys returned Response rate
Clinician 334a 213 63.7 %
Parent 291b 77 24.4 %
a 75 clinician surveys not mailed due to lack of IRB approval
b 118 parent surveys not mailed due to lack of IRB approval
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material (Botkin et al. 2012; Hendrix et al. 2013; Lewis et al.
2011). Keeping both public concerns and privacy laws in
mind, Region 4 sought and received IRB approval to proceed
with study activities in six of the seven states. Table 4 details
state-specific program information related to the project, in-
cluding that requiring any study protocol adaptations to com-
ply with state regulations. Two states, Indiana and Minnesota,
already had health department regulatory and follow-up sys-
tems in place to directly participate in the project. In Indiana,
the Indiana State Health Department (ISDH), in accordance
with legislation, acts as a centralized program providing diag-
nosis, follow-up, management, and family counseling for
infants and families identified with CH through the NBS
program. This project, therefore, fell under the ISDH’s autho-
rized scope of responsibilities. While Minnesota did have a
limited follow-up system in place, they were required to
obtain IRB approval, but the project was considered exempt.
While we defined “long-term follow-up” for the purposes of
this project as extended follow-up beyond the initial con-
firmed diagnosis of CH, only Illinois’ program extended
beyond the first three years of life at the time of our
study.tgroup
This is in contrast to the remaining four states (Illinois,
Kentucky, Michigan, and Wisconsin) which required sub-
mission to a state health department or specific university
IRB, depending on the operational framework of the
specific state NBS program. The reason for these differ-
ences is highlighted by the variation in NBS program
coordination. In comparison to Indiana, for example, the
Wisconsin NBS program is administered by the Wiscon-
sin Department of Health (WDPH) and the testing is
performed at the State Laboratory of Hygiene (WSLH)
which is part of the University of Wisconsin. WDPH’s
role is to provide policy decisions (e.g., which disorders
screened for) and be responsible for the technical opera-
tions of the program such as blood collection, testing,
reporting, and short-term follow-up. All NBS data (testing
results) are kept at WSLH, necessitating submission for
IRB approval through the University of Wisconsin. How-
ever, the University of Wisconsin does not store parent
contact information (addresses or phone numbers), as this
is housed by the WDPH, from which IRB approval was
not sought or approved for this study, creating some
difficulty with parent survey collection.
Despite a very diligent effort from CH Workgroup mem-
bers from the Public Health Laboratory of the Ohio Depart-
ment of Health, we were unable to collect data from Ohio
within the required timeframe. This was due to state laws that
prevented the NBS Program and laboratory access to public
health data. The study protocol was later submitted and ap-
proved through the state’s Title V, Children with Special
Table 4 NBS programs and the CH LTFU project by state
State NBS program
coordination
Legislation for NBS
program
STFU
program
LTFU
program
Required protocol
changes
IRB
submission
Full data
set
Illinois DPH Yes Yes Yes Yes DPH Yes
Indiana DPH, UA Yes Yes No No —— Yes
Kentucky DPH, UA Yes Yes No No DPH Yes
Michigan DPH, UA Yes Yes No Yes DPH Yes
Minnesota DPH, Yes Yes Yes Yes DPH Yes
Ohio DPH Yes Yes No Yes DPH No
Wisconsin DPH, UA Yes Yes No Yes UA No
NBS Newborn Screening, CH Congenital Hypothyroidism, LTFU Long-Term Follow-up (>1 year), STFU Short-Term Follow-up (<1 year), IRB
Institutional Review Board, DPH Department of Health, UA University Affiliation
Table 3 Multi-state public health project model
1) Establish Project Lead
a) Develop project outline
b) Create draft protocol
2) Centralize communication (Regional Collaborative (RC)
infrastructure/fixed meeting schedule)
3) Identify key stakeholders in each state
a) Clinicians
b) Public health department personnel
c) State lab personnel
d) Parents/patients
4) Create focused workgroup with clear goals and project timeline
5) Review project details and ratify study protocol
a) Allow open forum review
b) Allow protocol flexibility in language without compromising
integrity of data collection and analysis
c) Create de-identification process to ensure privacy compliance
6) Identify key differences between state laws and regulations influencing
the sphere of study
7) Identify potential costs
8) Institutional Review Board (IRB) submission
a) Utilize RC infrastructure to assist
b) Discuss any necessary modifications requested
9) Perform Study
10) Utilize RC for data management and analysis
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Health Care Needs Program, as they have broader authority to
contact their enrollees and access data from the state’s Birth
Defects Registry. Although we were unable to overcome these
barriers for the current study, the necessary IRB approval was
successfully obtained to participate in future long-term fol-
low-up activities. This was a valuable lesson that demonstrat-
ed the importance of careful scrutiny of public health process-
es, and the potential need to explore alternatives when faced
with challenging restrictions to study participation and data
collection.
Data Analysis
The states’ departments of health mailed, via certified post,
only de-identified raw data to the Region 4 evaluator at MPHI
to conduct all the data entry and analysis. While numerous
resources for data analysis existed within each state, it was
necessary to aggregate the data to strengthen the utility of the
results and the regional collaborative was a neutral site for
compiling multi-state data. In addition to individual state data
analysis, the ongoing participation of the Region 4 evaluator
allowed the CH Workgroup to discuss results and to begin
formulating state and region-specific long-term follow-up pro-
gram plans.
Future Direction & Benefits of Regional Collaboration
Since its adoption into national public health, NBS has grown
to include testing for dozens of congenital disorders. With this
expansion, there is a growing need for program accountabil-
ity; not simply to demonstrate the cost-benefit of NBS at the
state and national level (Schoen et al. 2002), but also to
develop a more standardized approach to management, genet-
ic counseling, education, and long-term follow-up of disorders
identified by NBS. The discrepancy between clinical manage-
ment guidelines for the long-term follow-up of CH and current
practices, as demonstrated by Korzeniewski et al., illustrates
this importance (Korzeniewski et al. 2013).
In addition to providing a means to evaluate CH, as it
pertains to NBS, this collaborative effort provided a number
of other benefits. Without exception, this project led to a
significant degree of introspection within each state program.
In fact, several states within Region 4, including Illinois,
Indiana, Michigan, and Minnesota, have already adopted
changes to improve their NBS protocols, data collection, and
follow-up programs based on their experience from this pro-
ject. The remaining states are all in the process of evaluating
their programs to improve services.
Michigan, for example, has decided to incorporate the
Clinician Survey as part of its routine follow-up and plans to
use the results to more accurately estimate the birth prevalence
of permanent CH in newborns and to reduce the number of
children with CH who are lost-to-follow-up. Minnesota began
long term follow-up in 2008 but, as a result of this study,
recognized the benefit of including data elements for
monitoring children regarding treatment decisions be-
yond the current two years of active monitoring. Fur-
thermore, Minnesota has incorporated new knowledge
into family education and now emphasizes the impor-
tance of maintaining a relationship with a specialist to
continuously monitor and provide medical management
for children diagnosed by NBS.
Regardless of design simplicity, multi-center, multi-state
public health studies require careful planning that includes a
detailed review of IRB and state law requirements. Adequate
participation from public health departments and key stake-
holders within the medical communities in each state is a
necessity. The data from this effort will be used to improve
state follow-up programs and aid in developing three years
follow-up guidelines for children diagnosed with CH. Future
regional projects such as this one will provide valuable insight
into the common practices of NBS programs and clinicians
with best practices.
Acknowledgments Supported by HRSA MCHB U22MC03963/
H46MC24092. Special thanks to the additional members of the CH
Workgroup: Irene Hong-McAtee, Carolyn Dunson-Dillard, Monika
Chaudhari, Barb Deluka, Courtney Eddy, Eileen White, Anna Starr,
Michelle Kempf-Weibel, Patricia Donohoue, Samantha Blum, Susan
Rose; and to the collaborative assistance from the public health and state
laboratory personnel from the Illinois Department of Public Health,
Indiana State Department of Health, Kentucky Department of Health,
Michigan Department of Community Health, Minnesota Department of
Health, Ohio Department of Health, andWisconsin Department of Health
Services.
Compliance with Ethical Standards
Disclosure of Conflict of Interest Kupper Wintergerst does not have
any conflict of interest to disclose.
Lisa Gorman does not have any conflict of interest to disclose.
Tracey Kreipe does not have any conflict of interest to disclose.
Patrick Zeller does not have any conflict of interest to disclose.
Erica Eugster does not have any conflict of interest to disclose.
Bill Young does not have any conflict of interest to disclose.
Karen Andruszewski does not have any conflict of interest to disclose.
Mary Kleyn does not have any conflict of interest to disclose.
Troi Cunningham does not have any conflict of interest to disclose.
Sandy Fawbush does not have any conflict of interest to disclose.
Nancy Vanderburg does not have any conflict of interest to disclose.
Joe Sockalosky does not have any conflict of interest to disclose.
Ram Menon does not have any conflict of interest to disclose.
Sharon Linard does not have any conflict of interest to disclose.
Gary Hoffman does not have any conflict of interest to disclose.
Gina Gembel does not have any conflict of interest to disclose.
Research Involving Human Participants and/or Animals All proce-
dures performed in studies involving human participants were in accor-
dance with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Congenital Hypothyroidism Long-Term Follow-up Project 471
Informed Consent Where exemption was not applicable and obtained,
informed consent was obtained from all individual participants included
in the study.
References
Berry, S. A., Jurek, A. M., Anderson, C., Bentler, K., & Region 4
Genetics Collaborative Priority 2 Workgroup. (2010). The inborn
errors of metabolism information system: A project of the Region 4
Genetics Collaborative Priority 2 Workgroup. Genet Med., 12(12
Suppl), S215–9. doi:10.1097/GIM.0b013e3181fe5d23.
Botkin, J. R., Rothwell, E., Anderson, R., Stark, L., Goldenberg, A.,
Lewis, M., Burbank, M., & Wong, B. (2012). Public attitudes
regarding the use of residual newborn screening specimens for
research. Pediatrics, 129(2), 231–238. doi:10.1542/peds. 2011-
0970.
European Society for Pediatric Endocrinology (ESPE). (1999). Revised
guidelines for neonatal screening programmes for primary congen-
ital hypothyroidism. Hormone Research, 52, 49–52. doi:10.1159/
000023433.
Fleischman, A., Thompson, J. D., & Glass, M. (2014). Systematic data
collection to inform policy decisions: integration of the region 4
stork (R4S) collaborative newborn screening database to improve
MS/MS newborn screening in Washington State. JIMD
Reproduction, 13, 15–21. doi:10.1007/8904_2013_266.
Hall, P. L., Marquardt, G., McHugh, D. M., Currier, R. J., Tang, H.,
Stoway, S. D., et al. (2014). Postanalytical tools improve perfor-
mance of newborn screening by tandem mass spectrometry.
Genetics in Medicine. doi:10.1038/gim.2014.62.
Hendrix, K. S., Meslin, E. M., Carroll, A. E., & Downs, S. M. (2013).
Attitudes about the use of newborn dried blood spots for research: a
survey of underrepresented parents. Academic Pediatrics, 13(5),
451–457. doi:10.1016/j.acap.2013.04.010.
Kemper, A. R., Ouyang, L., & Grosse, S. D. (2010). Discontinuation of
thyroid hormone treatment among children in the United States with
congenital hypothyroidism: findings from health insurance claims
data. BMC Pediatrics, 10, 9. doi:10.1186/1471-2431-10-9.
Klein, A. H., Agustin, A. V., & Foley, T. P. (1974). Successful laboratory
screening for congenital hypothyroidism. Lancet, 2(7872), 77–79.
doi:10.1016/S0140-6736(74)91637-7.
Korzeniewski, S. J., Grigorescu, V., Kleyn, M., Young,W. I., Birbeck, G.,
Todem, D., Romero, R., & Paneth, N. (2013). Transient hypothy-
roidism at 3-year follow-up among cases of congenital hypothyroid-
ism detected by newborn screening. Journal of Pediatrics, 162(1),
177–182. doi:10.1016/j.jpeds.2012.06.050.
Lewis, M. H., Goldenberg, A., Anderson, R., Rothwell, E., & Botkin, J.
(2011). State laws regarding the retention and use of residual new-
born screening blood samples. Pediatrics, 127(4), 703–712. doi:10.
1542/peds. 2010-1468.
McHugh, D., et al. (2011). Clinical validation of cutoff target ranges in
newborn screening of metabolic disorders by tandem mass spec-
trometry: a worldwide collaborative project. Genetics in Medicine,
13(3), 230–254. doi:10.1097/GIM.0b013e31820d5e67.
National Newborn Screening and Global Resource Center (NNSGRC).
(2006). National Newborn Screening 2006 Incidence Report. http://
genes-r-us.uthscsa.edu/sites/genes-r-us/files/resources/genetics/
2006datareport.pdf.
National Newborn Screening and Global Resource Center (NNSGRC).
(2011). Conditions screened by US programs: national newborn
screening status report. Retrieved from website: http://genes-r-us.
uthscsa.edu/sites/genes-r-us.uthscsa.edu/files/nbsdisorders.pdf.
Rose, S. R., & Brown, R. S. (2006). Update of newborn screening and
therapy for congenital hypothyroidism. Pediatrics, 117(6), 2290–
2303. doi:10.1542/peds. 2006-0915.
Schoen, E. J., Baker, J. C., Colby, C. J., & To, T. T. (2002). Cost-benefit
analysis of universal tandemmass spectrometry for newborn screen-
ing. Pediatrics, 110(4), 781–786. doi:10.1542/peds.110.4.781.
Szinnai, G. (2014). Genetics of normal and abnormal thyroid develop-
ment in humans. Best Practice & Research Clinical Endocrinology
& Metabolism, 28(2), 133–150. doi:10.1016/j.beem.2013.08.005.
U.S. Preventive Services Task Force. (1996). Screening for congenital
hypothyroidism. In: Guide to clinical preventive services. 2nd ed.
Washington, DC: U.S. Department of Health and Human Services;
503–507.
U.S. Preventive Services Task Force - Independent Expert Panel. (2008).
Screening for congenital hypothyroidism: U.S. Preventive Services
Task Force reaffirmation recommendation statement. NGC:006354
472 Wintergerst et al.
